Health Optimization Index
KPV (Lys-Pro-Val)
- Nick’s assessment
- Favorable
- Research evidence
- C, mixed evidence
- Attention
- 8.1 / 100▼ Falling this week
BioHarmony score
KPV is a three-amino-acid alpha-MSH fragment that reduced inflammation in mouse colitis models through PepT1 uptake and NF-kB pathway suppression, but it still has zero completed human RCTs. Dalmasso 2008 and Kannengiesser 2008 make the case compelling, while FDA and guideline gaps keep the score at 7.0–7.5/10.
Read the full report Benefits, risks and practical guidance.
Read Nick’s assessment Why it earned this rating
KPV (Lys-Pro-Val) is a 7.0–7.5/10 fit for people weighing gut health, inflammation control, and immune function, especially when the goal is a tracked experiment with clear endpoints. The strongest evidence anchor is Brzoska 2008: review of alpha-MSH, KPV, and related tripeptides in immune-mediated inflammatory disease models. Sung 2025 adds a second signal, but KPV (Lys-Pro-Val) still has gaps around large trials, long-term outcomes, responder profiles, or real-world adherence. That makes KPV (Lys-Pro-Val) useful for a defined reader, while weaker for broad anti-aging or catch-all wellness claims. In practice, KPV (Lys-Pro-Val) belongs after basics, diagnosis when relevant, and a stop rule based on symptoms, labs, sleep, or performance.
✅ Best for: Adults with gut inflammation, IBD-adjacent symptoms, IBS with a clear inflammatory component, atopic dermatitis experiments, or allergic-rhinitis experiments who have already done the boring clinical work: diagnosis, red-flag screening, first-line care, and basic gut foundations. KPV is most rational for users comfortable with n-of-1 experimentation, third-party-tested peptide sourcing, and a 4-8 week protocol window. It may also fit people comparing KPV with BPC-157 or low-dose naltrexone as part of a broader inflammation plan, as long as conventional IBD care remains primary.
❌ Avoid if: You need human RCT evidence before trying something, because KPV does not have it. Avoid during pregnancy or lactation, in children, in active malignancy unless a physician explicitly supervises, and in any undiagnosed GI red-flag situation: rectal bleeding, unexplained weight loss, fever, anemia, severe abdominal pain, or persistent diarrhea. Tested athletes should treat KPV as high-risk under WADA S0. Also avoid KPV if your only source is an unverified vendor, if you cannot evaluate certificates of analysis, or if you are tempted to use it instead of guideline-backed IBD or dermatology care. Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.
Share your experience
Your answers are optional and help other readers — they never change my score. How community input works.
One step left: confirm it’s you
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.
Make a 12-month prediction Will it rise or fall in the Index?
Choose a direction and your confidence. Correct predictions earn leaderboard points.
Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →